DEFA14A: Atai Life Sciences Secures $50 Million Financing and Reports Positive Phase 2b Results for BPL-003 in Treatment-Resistant Depression

Atai Life Sciences announced a $50 million private placement financing and positive topline results from Beckley Psytech's Phase 2b clinical study of BPL-003 for treatment-resistant depression, paving the way for a strategic acquisition and extended cash runway.

Summary

• Atai Life Sciences N.V. entered into subscription agreements for a private placement (PIPE Financing) to raise approximately $50 million in gross proceeds.
• The PIPE Financing involves the purchase of 18,264,840 ordinary shares at $2.19 per share and a pre-funded warrant to purchase 4,566,210 common shares at a purchase price of $2.18 per underlying share.
• Proceeds from the PIPE Financing are expected to be used for general corporate purposes, including working capital and advancing clinical development, extending the company's cash runway into the second half of 2027.
• The PIPE Financing was co-led by Ferring Ventures S.A. and Apeiron Investment Group Ltd., the family office of atai Co-Founder and Chairman Christian Angermayer, with participation from other institutional investors.
• Beckley Psytech, a private clinical-stage biopharmaceutical company, announced positive topline findings from its Phase 2b blinded clinical study of BPL-003 (intranasal mebufotenin benzoate) in 193 patients with moderate-to-severe treatment-resistant depression (TRD).
• The BPL-003 study met its primary and all key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in Montgomery-Åsberg Depression Rating Scale (MADRS) scores.
• At Day 29, a single 12 mg dose of BPL-003 led to an 11.1-point mean reduction in MADRS score from baseline (compared to 5.8 points in the 0.3 mg comparator arm, p=0.0038), while the 8 mg dose arm showed a 12.1-point mean MADRS reduction (p=0.0025).
• Efficacy results were statistically significant from as early as Day 2, with durable effects observed for both 8 mg and 12 mg doses out to Week 8 (Day 57).
• BPL-003 was generally well-tolerated, with over 99% of adverse events reported as mild or moderate, and no drug-related serious adverse events or suicide-related safety signals.
• The majority of patients were deemed ready for discharge at 90 minutes post-dose, suggesting BPL-003 could fit within a 2-hour in-clinic treatment paradigm.
• The positive Phase 2b results for BPL-003 have met the pre-agreed success criteria for the proposed strategic acquisition of Beckley Psytech by atai, which is now expected to progress to atai shareholder approval.
• The acquisition of Beckley Psytech, previously announced on June 2, 2025, involves issuing 105,044,902 Common Shares to Beckley Psytech shareholders not already owned by atai.

Sentiment

Score: 9

Explanation: The document conveys highly positive news, including successful clinical trial results for a key product candidate, a significant capital raise that extends the financial runway, and the progression of a strategic acquisition. These factors collectively indicate strong operational and strategic momentum.

Positives

• Successful private placement financing of approximately $50 million significantly extends the company's cash runway into the second half of 2027.
• BPL-003 Phase 2b study met its primary and all key secondary endpoints, demonstrating rapid, robust, and durable antidepressant effects in TRD patients.
• Statistically significant MADRS reductions were observed as early as Day 2 and sustained through Week 8 (Day 57) for both 8 mg and 12 mg doses.
• BPL-003 exhibited a favorable safety and tolerability profile, with over 99% of adverse events being mild or moderate and no drug-related serious adverse events or suicide-related safety signals.
• The short in-clinic time (majority of patients ready for discharge at 90 minutes post-dose) supports BPL-003's potential integration into existing interventional psychiatry treatment paradigms.
• The positive clinical data for BPL-003 fulfills the success criteria for the strategic acquisition of Beckley Psytech, which is expected to create a global leader in psychedelic-based mental health therapies.
• The acquisition is an all-stock deal, preserving cash, and includes lock-up agreements for significant shareholders, indicating long-term commitment.

Risks

• The PIPE Financing is subject to customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, which may not be satisfied in a timely manner.
• The company's estimate of cash runway into the second half of 2027 is based on assumptions that may prove to be incorrect, potentially leading to available capital resources being used sooner than expected.
• The proposed acquisition of Beckley Psytech may not be completed in a timely manner or at all, including the risk that required shareholder approvals are not obtained.
• There is a risk of failure to realize the anticipated benefits of the proposed acquisition, such as strategic value or financial synergies.
• The occurrence of any event, change, or other circumstance could give rise to the termination of the share purchase agreement for the acquisition.
• The announcement or pendency of the proposed acquisition could negatively affect the company's ability to retain and hire key personnel, or its operating results and business generally.

Future Outlook

The company expects the PIPE Financing to close in the third quarter of 2025, extending its cash runway into the second half of 2027. The strategic acquisition of Beckley Psytech is anticipated to progress to atai shareholder approval following the positive BPL-003 Phase 2b results. The company plans to engage with regulatory bodies, including the U.S. FDA, in the coming months to advance BPL-003 into Phase 3 clinical development. Further data from the BPL-003 open-label extension study and a Phase 2a open-label cohort are expected in the third quarter of 2025. The combined entity aims to become a global leader in short time in-clinic psychedelic-based mental health therapies and eventually transform into a fully integrated commercial company.

Management Comments

• Cosmo Feilding Mellen, CEO and Co-Founder of Beckley Psytech, stated that the study's achievement of primary and secondary endpoints is an important milestone, reinforcing BPL-003's potential as a viable treatment option with rapid, durable efficacy, favorable tolerability, and short in-clinic time.
• Srinivas Rao, CEO and Co-Founder of atai, expressed strengthened confidence in BPL-003 as a transformative psychedelic therapy, offering rapid and durable antidepressive effects with minimal in-clinic time, and looks forward to engaging with regulators for Phase 3 development.
• Christian Angermayer, Co-Founder and Chairman of atai, commented that the financing positions atai to accelerate its efforts in delivering new therapeutic options and expressed confidence that the trial results will support robust discussions with the FDA for a clear Phase 3 plan by early 2026.
• Jean-Frederic Paulsen, Chairman of Ferring Ventures S.A., highlighted psychedelics' remarkable potential and expressed pleasure in expanding their investment to support atai in pioneering the next generation of mental health treatments.

Industry Context

The announcement positions Atai Life Sciences and its impending acquisition, Beckley Psytech, at the forefront of the rapidly evolving psychedelic-based mental health treatment industry. The positive Phase 2b results for BPL-003, a rapid-acting psychedelic, address a significant unmet need in treatment-resistant depression (TRD), a condition affecting millions globally. The focus on a short in-clinic treatment time aligns with the established interventional psychiatry paradigm set by Johnson & Johnson's Spravato (esketamine), suggesting a commercially scalable approach. This development could accelerate the acceptance and integration of psychedelic therapies into mainstream healthcare systems, potentially shifting treatment paradigms for severe mental health conditions.

Comparison to Industry Standards

• BPL-003's single 8 mg and 12 mg doses demonstrated statistically significant and clinically meaningful reductions in MADRS scores compared to a 0.3 mg low-dose active control, indicating strong efficacy.
• The rapid onset of action (statistically significant improvements as early as Day 2) and durable effect (maintained out to Week 8) for BPL-003 compare favorably to traditional antidepressants which often take weeks to show effect.
• BPL-003's favorable tolerability profile, with over 99% of adverse events being mild or moderate and no drug-related serious adverse events or suicide-related safety signals, is a critical safety advantage in the psychedelic space.
• The average time to meet readiness for discharge criteria across all BPL-003 arms was within two hours of dosing, with the majority of patients ready for discharge at 90 minutes post-dose, directly comparable to the 2-hour in-clinic interventional psychiatry treatment paradigm established by Spravato (esketamine).
• While no head-to-head trials were conducted, BPL-003's single-dose MADRS response was noted as comparable to published results from a twice-weekly Spravato monotherapy dosing regimen, suggesting potential for reduced patient burden and improved infrastructure utilization due to fewer required dosing sessions.
• Spravato, a nasal spray for TRD, achieved global annual sales of $1,077 million in 2024, demonstrating a significant market for in-clinic TRD treatments that BPL-003 aims to penetrate and potentially improve upon with its longer duration of effect from fewer doses.

Related Party Transactions

• Apeiron Investment Group Ltd., the family office of Christian Angermayer (Co-Founder and Chairman of atai Life Sciences N.V.), participated in the PIPE Financing.

Stakeholder Impact

• Shareholders: Potential for increased share value due to positive clinical data, extended financial runway, and strategic growth through acquisition. However, there will be dilution from the issuance of new shares in the PIPE and for the acquisition.
• Patients: Significant potential for a new, rapid-acting, and durable treatment option for treatment-resistant depression (BPL-003), addressing a high unmet medical need.
• Employees: Integration of Beckley Psytech and atai teams may lead to new organizational structures and opportunities within the combined entity.
• Creditors: Improved financial stability and extended cash runway due to the capital raise may enhance the company's creditworthiness.

Next Steps

• Closing of the PIPE Financing is expected in the third quarter of 2025.
• The strategic acquisition of Beckley Psytech is expected to progress to atai shareholder approval stage.
• Planning for Phase III studies of BPL-003 will commence with appropriate regulatory bodies, including the U.S. FDA, in the coming months.
• Topline data from the 8-week open-label extension (OLE) stage of the BPL-003 study is expected in the third quarter of 2025.
• Topline data from the Phase 2a open-label cohort investigating a 2-dose induction model for BPL-003 is expected in the third quarter of 2025.
• An FDA End of Phase 2 meeting request for BPL-003 is anticipated.
• The combined atai-Beckley entity aims to transform from a clinical-stage biotech into a fully integrated commercial company over time.

Key Dates

Recommendation

Keywords

Treatment-Resistant Depression, Psychedelic Therapy, BPL-003, Mebufotenin, 5-MeO-DMT, Private Placement, PIPE Financing, Beckley Psytech, Acquisition, Clinical Trial Results, Phase 2b, Mental Health, Biopharmaceutical, Drug Development, Cash Runway, Corporate Strategy